Literature DB >> 2320602

Recombinant tumor necrosis factor-alpha chronically administered in rats: lack of cachectic effect.

B J Mullen1, R B Harris, J S Patton, R J Martin.   

Abstract

Recombinant human tumor necrosis factor-alpha (rHuTNF) was injected into rats to test its reported cachectic effects. Rats were subcutaneously injected daily at 1730 hr with either saline or rHuTNF (0.25 mg/kg body wt) for either 5 or 14 days. Daily food intakes were significantly depressed only for the first day and first two days of rHuTNF injection in animals treated for 5 days and 14 days, respectively. There were no significant differences in daily body weights among the groups. Analysis of carcass composition revealed no significant differences in percentage of lipid or protein. Liver and inguinal pad weights were not significantly different. In vitro determination of lipogenesis showed it was enhanced in the inguinal pad and depressed in the liver only after 14 days of treatment. These results demonstrate that although in vivo rHuTNF may specifically alter tissue metabolism, it does not, by itself, result in a sustained cachectic effect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2320602     DOI: 10.3181/00379727-193-43042

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  3 in total

1.  The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice.

Authors:  Annabelle Z Caron; Sonia Haroun; Elisabeth Leblanc; Frédéric Trensz; Chantal Guindi; Aziz Amrani; Guillaume Grenier
Journal:  BMC Musculoskelet Disord       Date:  2011-08-15       Impact factor: 2.362

2.  TNF-Alpha in the Locomotor System beyond Joints: High Degree of Involvement in Myositis in a Rabbit Model.

Authors:  Sture Forsgren; Lina Renström; Craig Purdam; James E Gaida
Journal:  Int J Rheumatol       Date:  2012-03-07

Review 3.  Cancer cachexia.

Authors:  M J Tisdale
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.